The Food and Drug Administration has canceled a meeting to review Eli Lilly’s antidepressant Cymbalta for a new use against chronic pain.
The agency says the Jan. 28 meeting has been canceled “to allow time for the FDA to review new information,” about the proposed use.
Shares of the Indianapolis-based company fell 60 cents to $35.22 in midday trading.
Lilly withdrew an earlier application in November 2008 after FDA reviewers questioned the methodology and dosing of some of the company’s trials.
The company submitted a new application last summer that included a study of Cymbalta for chronic pain caused by osteoarthritis, along with new data from a study of lower back pain.
© 2010 Associated Press. Displayed by permission. All rights reserved.
